ArticleEJVES vascular forum2026
Early Outcomes of Zone 2 Thoracic Endovascular Aortic Repair with an Integrated Branch Stent Graft for the Left Subclavian Artery: Evidence from a Western Centre.
Article in EJVES vascular forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Aorta Is One Organ; Our Response Is Not: A Global Case for Systems Redesign in Acute Aortic Syndromes.Journal of clinical medicine · 2026Review
- Emergency endovascular repair of blunt thoracic aortic injury-related pseudoaneurysm using a castor single-branched stent graft: a case report and literature review.Frontiers in cardiovascular medicine · 2026Article
- Clinically silent early proximal seal failure with suspected interval distal endograft displacement after hybrid zone 2 thoracic endovascular aortic repair in severe arch tortuosity: a case report with 1-year follow-up.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thoracic endovascular aortic repair (TEVAR) is widely used for thoracic aortic diseases, most commonly with a proximal landing in Ishimaru zone 3. When an adequate proximal sealing zone is lacking, extension into zone 2 is required, often necessitating left subclavian artery (LSA) revascularisation. The Castor single branched stent graft provides a fully endovascular solution for zone 2 TEVAR by incorporating an antegrade branch for the LSA. This study reports a single centre Western experience with this device. Method: A retrospective analysis was conducted on 15 consecutive patients undergoing elective zone 2 TEVAR with the Castor single branched stent graft between July 2023 and December 2025. Indications included thoracic aortic aneurysm, subacute or chronic Stanford type B dissection, and penetrating aortic ulcer. The primary endpoint was technical success, defined as accurate deployment without type I or III endoleak and with preserved LSA patency. Secondary endpoints included clinical success, access related complications, intensive care unit (ICU) and hospital stays, re-intervention, and death. Follow up consisted of serial computed tomography angiography. Results: The mean age was 63.9 ± 11 years, and 87% of patients were men. Technical and clinical success were achieved in 14 patients (93%). One patient required adjunctive covered stenting of the LSA for incomplete branch expansion. There were no access related complications or 30 day deaths. Mean ICU and hospital stays were 1.2 ± 0.6 days and 15.3 ± 9.6 days, respectively. Over a mean follow up of 13.5 ± 8.4 months, all LSA branches remained patent, with no endoleak, device migration, or re-intervention. Conclusion: Zone 2 TEVAR using the Castor single branched stent graft appears feasible, safe, and effective in a Western population. In this small elective series, LSA branch patency was maintained and no device related re-intervention occurred during available follow up. Larger studies with longer follow up are needed to assess durability and longer term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.